Risk of Osteoporotic Fractures After Discontinuation of Menopausal Hormone Therapy: Results From the E3N Cohort
Authors:
- Agnès FournierAFAgnès Fournier
- Marie-Christine Boutron-RuaultMBMarie-Christine Boutron-Ruault
- Françoise Clavel-ChapelonFCFrançoise Clavel-Chapelon
Open Access
- 9 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 174 (1) , 12-21
Abstract
While current use of menopausal hormone therapy (MHT) reduces the risk of osteoporotic fractures, epidemiologic studies suggest that protection wears off rapidly after discontinuation of treatment. The authors identified 5,589 first osteoporotic fractures (2,235 major osteoporotic fractures) among 70,182 postmenopausal women from the French E3N cohort (1992–2008) and used Cox multivariate proportional hazards regression models to estimate hazard ratios. Persistence of protection against major osteoporotic fractures after MHT discontinuation was only observed when MHT had been used for at least 5 years, with a slightly more important decrease within the 5 years after discontinuation (compared with never use of MHT, hazard ratio = 0.68, 95% confidence interval: 0.50, 0.92) than beyond 5 years (hazard ratio = 0.83, 95% confidence interval: 0.69, 0.99); the P value for homogeneity between the 2 estimates was not significant. Oral estrogen use and transdermal estrogen use conveyed similar estimates in past users. Among current users, the authors confirmed a protective effect of MHT against risk of osteoporotic fractures. These findings, which relied on a number of MHT combinations, suggested that such therapies should be used for 5 years or more for reducing risk of fracture after treatment discontinuation.Keywords
This publication has 42 references indexed in Scilit:
- Proteins, Dietary Acid Load, and Calcium and Risk of Postmenopausal Fractures in the E3N French Women Prospective StudyJournal of Bone and Mineral Research, 2008
- The Effects of Tibolone in Older Postmenopausal WomenNew England Journal of Medicine, 2008
- Issues concerning the use of hormone replacement therapy and risk of fracture: a population‐based, nested case‐control studyBritish Journal of Clinical Pharmacology, 2007
- Risk of Subsequent Fracture After Low-Trauma Fracture in Men and WomenJAMA, 2007
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trialsMenopause, 2004
- Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) studyMenopause, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001